Last updated: April 29, 2026
CELGENE CORP. v. TEVA (2:18-cv-14366): Litigation Summary and Patent-Strategy Implications
What is the case and who are the parties?
- Case: Celgene Corporation v. Teva Pharmaceuticals USA, Inc.
- Court / Docket: U.S. District Court, District of Massachusetts; Case No. 2:18-cv-14366
- Parties:
- Plaintiff: Celgene Corporation
- Defendant: Teva Pharmaceuticals USA, Inc.
What claims does the litigation typically involve in this posture?
In Hatch-Waxman Paragraph IV litigation between a brand innovator and an ANDA filer, the dispute typically centers on whether the ANDA product infringes one or more listed patents and whether those patents are invalid or unenforceable. This docket number is consistent with a generic launch-readiness infringement action filed by the brand against the ANDA applicant.
Case-level specifics (asserted patent(s), ANDA drug, filing date, claim construction positions, trial schedule, and dispositive rulings) are required to produce a complete litigation summary. Without the pleadings and orders, any statement about the asserted patents, infringement theories, defenses, claim construction results, or final outcome would not be complete and accurate.
What does the available record allow versus what it does not?
A litigation summary suitable for investment-grade patent analysis must map:
- Asserted patent set (numbers, priority dates, expiration posture)
- ANDA product and carve-outs (formulation, dosage, labeling, exclusivities)
- Procedural posture (dismissals, summary judgment rulings, trial, settlement terms)
- Infringement construction (claim terms, limiting features, non-infringement arguments)
- Invalidity (anticipation/obviousness, written description/enablement, prosecution history)
- Final judgment (injunction scope, at-risk launch timing, post-judgment motions)
Those elements are not provided in the prompt, and the docket record content is not included. Under the constraints, this response must omit incomplete analysis rather than infer.
Litigation-Strategy Lens (Patent Analyst Framework)
How do these cases usually break down technically?
Where the asserted patents involve small-molecule formulations or dosing regimens, the infringement analysis usually follows a pattern:
- Literal infringement: ANDA composition and manufacturing specs matched to each claim element
- Doctrine of equivalents: overlap on formulation parameters not reproduced identically
- Process elements: method claims often turn on evidence about manufacturing steps and controls
Where patents involve biological or method-of-use claims, the dispute often turns on:
- Therapeutic indication mapping: label-driven infringement and patient population constraints
- Dosage regimen interpretation: whether the ANDA label induces performance of every step
What investors typically watch in the procedural timeline
In these matters, high-value milestones include:
- Early claim construction rulings that narrow or broaden claim scope
- Summary judgment outcomes on invalidity themes (especially obviousness)
- Daubert and expert admissibility decisions that swing claim-element proof
- Final judgment and at-risk launch windows after injunction stays or settlements
What patent-management outcomes matter commercially
- Whether the court sustains invalidity on key claims or leaves them intact
- Whether infringement is found but with limited remedy or design-around opportunities
- Whether a “thin” claim construction undermines enforceability across dosages or formulations
Case Outcome and Remedy
No outcome details, remedy, or settlement terms are provided in the prompt. Without docket orders, this section would be speculative and would not meet the “complete and accurate” requirement.
Key Takeaways
- Docket identified: Celgene Corporation v. Teva Pharmaceuticals USA, Inc., 2:18-cv-14366 in the District of Massachusetts.
- Actionable patent conclusions require the operative record (complaint, ANDA description, asserted patent numbers, claim construction and summary judgment orders, and final judgment). Those are not included, so a litigation outcome or infringement/invalidity analysis cannot be stated accurately here.
FAQs
-
What is this lawsuit about at a high level?
It is a brand-versus-ANDA patent infringement dispute consistent with a Hatch-Waxman Paragraph IV posture.
-
Which patents were asserted in 2:18-cv-14366?
Not provided in the prompt; cannot be stated accurately without the complaint and related filings.
-
What is the procedural stage and result?
Not provided in the prompt; cannot be stated accurately without orders or judgment.
-
Does the case involve invalidity (anticipation/obviousness) defenses?
Typically yes in this posture, but the specific invalidity grounds cannot be identified without the pleadings and rulings.
-
What commercial impact would the outcome have?
It would determine whether Teva can launch “at risk” and how long Celgene’s exclusivity window remains protected, but the actual impact depends on the court’s specific rulings or settlement.
References (APA)
[1] U.S. District Court, District of Massachusetts. Celgene Corporation v. Teva Pharmaceuticals USA, Inc., No. 2:18-cv-14366.
